Insilico Medicine announced the development of a peptide targeting GLP-1R for cardiometabolic disease, designed using its advanced generative biologics engine in only 72 hours. According to the company, the achievement demonstrates the platform’s potential to accelerate biologic drug discovery and optimize the design of therapeutic peptides.
The company said that the generative biologics engine integrates artificial intelligence with molecular design, enabling rapid generation and evaluation of peptide structures with desired therapeutic properties. Insilico claims that the engine can significantly shorten the discovery timeline for novel peptide drugs compared to conventional methods, which typically take months or years.
According to Insilico, the GLP-1R-targeted peptide was created as part of its ongoing research into cardiometabolic diseases, including obesity and type 2 diabetes. The company stated that the peptide underwent in silico validation and optimization processes to enhance receptor binding, stability and efficacy profiles.
The company said that its AI platform combines molecular generation, protein modeling and prediction algorithms to produce biologics with improved safety and activity parameters. Insilico claims that this approach could transform the biologics discovery process by expanding the pipeline of viable therapeutic candidates across multiple disease areas.
The company added that the successful 72-hour development of the peptide marks a milestone in its broader effort to apply generative AI technologies to biologics research, with potential applications extending into metabolic, oncology and rare disease therapies.
